What is the national unified retail price of ensifentrine-Ohtuvayre?

Ensifentine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre is a new dual-action inhaled drug. It is currently mainly used for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD) . Although the clinical application of exefantine has been highly praised worldwide, its original drug (Ohtuvayre) has not yet been officially launched in China, so there is no clear information on the specific domestic selling price. However, it is reported that Ensefentine has been launched in some administrative regions and may officially enter the wider Chinese market in the future as clinical data accumulates and market demand increases.

Overseas, particularly in the United States, the price of exefantine has been made public. Taking the US version of the original drug as an example, Ohtuvayre with a specification of 3mg/2.5mL (60 doses) is priced at more than 40,000 yuan per box. This price is based on the market pricing of the original drug. The actual selling price may be affected by exchange rate fluctuations, regional differences and sales policies. Although the price is relatively high, exefentine is still considered a treatment option worth investing in given its effectiveness in treating COPD and its ability to provide longer symptom relief.

At present, in the Chinese market, the price and medical insurance reimbursement of exefantine have not yet been fully determined. With the clinical verification and market penetration of the drug, it is expected that the pricing of exefantine will gradually be clarified in the next few years, and generic versions will enter the market to reduce treatment costs. If exefantine can be included in medical insurance, it will play a positive role in alleviating the treatment burden on patients.

In general, as a new typeCOPD treatment drug, exefantine has high efficacy and good patient tolerance. It is expected to be officially launched in the Chinese market in the future and compete with other drugs. When choosing this drug, patients should pay attention to the doctor's advice and choose an appropriate treatment plan according to their own situation.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html